Dendreon High Paying Jobs, Compensation Information and Expert Network Connections

lightbulbWhat are the highest paying jobs at Dendreon?

Dendreon is a biotechnology company. Its lead product, Provenge, is an immunotherapy for prostate cancer. It consists of a mixture of the patient's own blood cells that have been incubated with the Dendreon PAP-GM-CSF fusion protein. Phase III clinical trial results demonstrating a survival benefit for prostate cancer patients receiving the drug were presented at the AUA meeting on April 28, 2009. After going through the approval process, Provenge was given full approval by the FDA on April 29, 2010. Dendreon's stock value fell 66% on August 4, 2011, after abandoning its forecast for its debut drug Provenge. In November 2014, Dendreon filed for Chapter 11 bankruptcy protection and shortly afterwards announced that it had reached agreements on the terms of a financial restructuring with certain bond holders. On February 20, 2015, Valeant Pharmaceuticals received approval to purchase all Dendreon assets. On January 9, 2017 Sanpower Group agrees to acquire Dendreon from Valeant for $819.9 million In June 2017, Sanpower Group, a Chinese conglomerate, purchased Dendreon from Valeant for $820 million.
stats icon
Total value of jobs:
stats icon
Total Jobs:
stats icon
Average Pay:
stats icon
Total Experts:
stats icon
% Masters:

Top Experts at Dendreon

Dendreon Compensation

Account Manager



Average Compensation:$92,917

View All Compensation view all icon